Evercore ISI maintains Outperform on Insmed, cuts target to $160

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Evercore ISI Group analyst Josh Schimmer maintained an Outperform rating on Insmed (NASDAQ: INSM) while lowering the price target to $160 from $162.

powered bylight_fuzz_icon
43694746

*this image is generated using AI for illustrative purposes only.

Evercore ISI Group analyst Josh Schimmer has maintained an Outperform rating on Insmed (NASDAQ: INSM). The firm adjusted its valuation by lowering the price target to $160 from $162.

The rating update reflects a revised outlook on the stock's potential while retaining a positive stance on its performance. The new price target represents a slight decrease from the previous estimate of $162.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What factors contributed to the slight reduction in Insmed's price target?

How might Insmed's upcoming clinical trials impact its stock performance?

What are the potential market reactions to future earnings reports?

like19
dislike

JP Morgan maintains Overweight on Insmed, cuts target to $179

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

JP Morgan analyst Jessica Fye maintained an Overweight rating on Insmed (NASDAQ: INSM) and lowered the price target to $179 from $180.

powered bylight_fuzz_icon
42472205

*this image is generated using AI for illustrative purposes only.

JP Morgan analyst Jessica Fye maintained an Overweight rating on Insmed (NASDAQ: INSM) while adjusting the stock's price target. The firm reduced the target to $179 from the previous $180. The rating update reflects a continued positive outlook on the stock despite the minor adjustment in the valuation target.

Rating and Target Details

The decision to keep the Overweight rating suggests confidence in Insmed's performance potential relative to the broader market. The $1 reduction in the price target brings the new valuation to $179.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What factors could drive Insmed's stock to surpass the revised $179 price target?

How might upcoming clinical trial results influence Insmed's market performance?

What competitive pressures could impact Insmed's ability to maintain its Overweight rating?

like16
dislike